Efineptakin alfa
- Generic Name
- Efineptakin alfa
- Drug Type
- Biotech
- CAS Number
- 2026634-47-7
- Unique Ingredient Identifier
- 3K3WC6MT6P
- Background
Efineptakin alfa (also known as NT-I7) is a long-acting human interleukin-7 (IL-7) fusion protein that promotes T-cell development, contributing to the immune response. Compared to endogenous IL-7, NT-I7 is more stable and potent, has a longer half-life, and has better bioavailability. This drug is currently being investigated in the areas of oncology, immunology, and infectious disease.
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
- Conditions
- High Grade Astrocytic TumorRecurrent Glioblastoma, IDH-WildtypeRecurrent Gliosarcoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Biopsy
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 44
- Registration Number
- NCT05465954
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients
- Conditions
- Recurrent Glioblastoma
- Interventions
- First Posted Date
- 2022-01-13
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05191784
- Locations
- 🇰🇷
Seoul St.Mary's Hospital of the Catholic University of Korea, Seoul, Korea, Republic of
Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy
- Conditions
- Refractory High Grade B-Cell LymphomaRefractory Transformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRefractory Diffuse Large B-cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- NeoImmuneTech
- Target Recruit Count
- 57
- Registration Number
- NCT05075603
- Locations
- 🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center, Detroit, Michigan, United States
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
- Conditions
- Non Small Cell Lung CancerNon-Small Cell Lung CarcinomaCarcinoma, Non-Small-Cell LungNon-Small Cell Lung CancerNonsmall Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- NeoImmuneTech
- Target Recruit Count
- 83
- Registration Number
- NCT04984811
- Locations
- 🇺🇸
Zangmeister Cancer Center, Columbus, Ohio, United States
🇺🇸Tennessee Oncology - Nashville, Nashville, Tennessee, United States
🇺🇸University of South Alabama, Mobile, Alabama, United States
A Study to Evaluate the Safety and Efficacy of GX-I7 in Elderly Patients With Asymptomatic or Mild Symptoms of COVID-19
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- PT Kalbe Genexine Biologics
- Target Recruit Count
- 210
- Registration Number
- NCT04810637
- Locations
- 🇮🇩
Mitra Keluarga Kelapa Gading, Jakarta Pusat, Indonesia
🇮🇩Mitra Keluarga Kemayoran, Jakarta Pusat, Indonesia
NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2025-03-24
- Target Recruit Count
- 12
- Registration Number
- NCT04781309
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Safety and Preliminary Efficacy Study of GX-I7 in Patients With COVID-19
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2022-11-30
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04730427
- Locations
- 🇰🇷
Borame Medical Center, Seoul, Korea, Republic of
NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma
- Conditions
- Gastric or Gastro-esophageal Junction (GEJ) or Esophageal Adenocarcinoma (EAC)
- Interventions
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- NeoImmuneTech
- Target Recruit Count
- 10
- Registration Number
- NCT04594811
- Locations
- 🇵🇱
Centrum Medyczne Klara, Czestochowa, Poland
🇵🇱Pratia Poznań, Skorzewo, Poland
🇺🇸The Center for Cancer & Blood Disorders, Fort Worth, Texas, United States
NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery
- Conditions
- Recurrent Laryngeal Squamous Cell CarcinomaRecurrent Hypopharyngeal Squamous Cell CarcinomaResectable Oropharyngeal Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaRecurrent Oral Cavity Squamous Cell CarcinomaRecurrent Oropharyngeal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Hyunseok Kang, MD
- Target Recruit Count
- 4
- Registration Number
- NCT04588038
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
A Trial of NT-I7 in COVID-19 (SPESELPIS)
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- NeoImmuneTech
- Target Recruit Count
- 7
- Registration Number
- NCT04501796
- Locations
- 🇺🇸
Nih/Niaid, Bethesda, Maryland, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.